TD Cowen raised the firm’s price target on Boston Scientific (BSX) to $110 from $100 and keeps a Buy rating on the shares. The firm expects the company will achieve its goal of being the top-performing large-cap med tech company in 2024-26 if not longer. This can be accomplished with strong momentum in its commercial portfolio and contributions from new, differentiated products launched from its pipeline.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BSX:
- Boston Scientific price target raised to $107 from $98 at Citi
- Boston Scientific price target raised to $101 from $98 at Canaccord
- Boston Scientific participates in a conference call with Truist
- Boston Scientific to acquire Intera Oncology, terms not disclosed
- Boston Scientific Launches 2025 Incentive Programs